Abstract | BACKGROUND: OBJECTIVE: METHODS: In this multicenter, open-label study, patients with chronic migraine (≥ 15 headache days/month) who were triptan overusers ( triptan intake ≥ 10 days/month for ≥ 3 months) received botulinum toxin type A (95-130 U) at baseline and month three. Headache (HA) frequency and medication use were assessed with patient diaries, and headache-related disability by means of the MIDAS and Headache Impact Test-6 questionnaires. RESULTS: Of 53 patients enrolled (mean age ± standard deviation, 46.5 years ± 8.4; 47 [88.7%] females), 48 (90.6%) completed the study at month six. Based on headache diaries, significant (P ≤ 0.0002) decreases from baseline were observed for days per month with headache/migraine, days with any acute headache medication use, days with triptan use, and triptan doses taken per month. A significant (P < 0.0001) increase from baseline in headache-free days per month was also observed. Prescription medication costs for acute headache medications decreased significantly, including significant reductions in triptan costs (mean reduction of -C$106.32 ± 122.87/month during botulinum toxin type A prophylaxis; P < 0.0001). At baseline, 78% of patients had severe disability (MIDAS score) and 86.8% had severe impact due to headache (HIT-6 scores); at month six, this decreased to 60% and 68%, respectively. CONCLUSIONS:
|
Authors | Suzanne N Christie, Rose Giammarco, Marek Gawel, Gordon Mackie, Jonathan Gladstone, Werner J Becker |
Journal | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
(Can J Neurol Sci)
Vol. 37
Issue 5
Pg. 588-94
(Sep 2010)
ISSN: 0317-1671 [Print] England |
PMID | 21059503
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Neuromuscular Agents
- Tryptamines
- Botulinum Toxins, Type A
|
Topics |
- Adolescent
- Adult
- Aged
- Analysis of Variance
- Botulinum Toxins, Type A
(economics, therapeutic use)
- Disability Evaluation
- Drug Costs
(statistics & numerical data)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Migraine Disorders
(drug therapy, economics, prevention & control)
- Neuromuscular Agents
(economics, therapeutic use)
- Surveys and Questionnaires
- Treatment Outcome
- Tryptamines
(adverse effects, economics)
- Young Adult
|